No abstract

No abstract

No abstract

Glipizide is a sulfocyelohexylurea with proven antidiabetic properties. Glipizide treated patients have been compared during an initial period of three months with three groups of comparable patients receiving single agent therapy, viz. glibenelamide, ehlorpropamide, or phenformin. The drug seems to be an easy-tohandle antidiabetie agent, active in a dosage from 2.5 to 20 mg in patients with matqrity-onset diabetes, not satisfactorily controlled on diet alone. The frequency of primary failures was slightly higher than with glibenclamide and chlorpropamide, but on the contrary the tolerance was better and the side effects negligible.Glipizide is a new compound of the sulfonylurea type, synthetised by Ambrogi in 1971 [1]. This author concluded, after animal experimentation, that:1. the compound was at least 100 times more potent than tolbutamide in decreasing blood glucose levels in fasted normal animals, and 2. the compound antagonized hyperglycemia induced by glucose loads and increased insulinemia [2].Administration of the drug to non-diabetic [3] and diabetic subjects [4] demonstrates that glipizide, given in a daily dose of 2.5 mg to 15.0 mg, is an effective blood sugar lowering drug and is well tolerated.The objectives of our study were:

No abstract